Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer

Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer

Lung cancer remains the leading cause of cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, with nearly half of all patients diagnosed at an advanced stage. Immune checkpoint inhibitors (ICIs) harness the host immune system to combat malign...

Full description

Saved in:
Bibliographic Details
Main Authors: Emily Wolf, Guilherme Sacchi de Camargo Correia, Shenduo Li, Yujie Zhao, Rami Manochakian, Yanyan Lou
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Vaccines
Subjects:
non-small-cell lung cancer
immune checkpoint inhibitors
immunotherapy
antibody–drug conjugate
bispecific antibodies
monoclonal antibodies
Online Access:https://www.mdpi.com/2076-393X/13/2/128
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2076-393X/13/2/128

Similar Items